Literature DB >> 29066599

IL-6-Type Cytokine Signaling in Adipocytes Induces Intestinal GLP-1 Secretion.

Stephan Wueest1,2, Céline I Laesser3,2, Marianne Böni-Schnetzler4,5, Flurin Item3,2, Fabrizio C Lucchini3,2,6, Marcela Borsigova3,2, Werner Müller7, Marc Y Donath4,5, Daniel Konrad1,2,6.   

Abstract

We recently showed that interleukin (IL)-6-type cytokine signaling in adipocytes induces free fatty acid release from visceral adipocytes, thereby promoting obesity-induced hepatic insulin resistance and steatosis. In addition, IL-6-type cytokines may increase the release of leptin from adipocytes and by those means induce glucagon-like peptide 1 (GLP-1) secretion. We thus hypothesized that IL-6-type cytokine signaling in adipocytes may regulate insulin secretion. To this end, mice with adipocyte-specific knockout of gp130, the signal transducer protein of IL-6, were fed a high-fat diet for 12 weeks. Compared with control littermates, knockout mice showed impaired glucose tolerance and circulating leptin, GLP-1, and insulin levels were reduced. In line, leptin release from isolated adipocytes was reduced, and intestinal proprotein convertase subtilisin/kexin type 1 (Pcsk1) expression, the gene encoding PC1/3, which controls GLP-1 production, was decreased in knockout mice. Importantly, treatment with the GLP-1 receptor antagonist exendin 9-39 abolished the observed difference in glucose tolerance between control and knockout mice. Ex vivo, supernatant collected from isolated adipocytes of gp130 knockout mice blunted Pcsk1 expression and GLP-1 release from GLUTag cells. In contrast, glucose- and GLP-1-stimulated insulin secretion was not affected in islets of knockout mice. In conclusion, adipocyte-specific IL-6 signaling induces intestinal GLP-1 release to enhance insulin secretion, thereby counteracting insulin resistance in obesity.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29066599     DOI: 10.2337/db17-0637

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  15 in total

Review 1.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

Review 2.  The role of adipocyte-specific IL-6-type cytokine signaling in FFA and leptin release.

Authors:  Stephan Wueest; Daniel Konrad
Journal:  Adipocyte       Date:  2018-08-03       Impact factor: 4.534

Review 3.  Review: the Roles and Mechanisms of Glycoprotein 130 Cytokines in the Regulation of Adipocyte Biological Function.

Authors:  Dufang Ma; Yong Wang; Guofeng Zhou; Yongcheng Wang; Xiao Li
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

4.  Liraglutide Is Protective against Brain Injury in Mice with Febrile Seizures by Inhibiting Inflammatory Factors.

Authors:  Xing Wang; Fei Yang; Liling Deng; Di Qiu; Yao Liu; Yang Kang
Journal:  Comput Math Methods Med       Date:  2022-04-29       Impact factor: 2.809

Review 5.  Regulation of Energy Expenditure and Brown/Beige Thermogenic Activity by Interleukins: New Roles for Old Actors.

Authors:  María Del Carmen García; Patricia Pazos; Luis Lima; Carlos Diéguez
Journal:  Int J Mol Sci       Date:  2018-08-29       Impact factor: 5.923

6.  Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice.

Authors:  Charlotte B Christiansen; Sara J Lind; Berit Svendsen; Emilie Balk-Møller; Tina Dahlby; Rune E Kuhre; Bolette Hartmann; Thomas Mandrup-Poulsen; Carolyn F Deacon; Nicolai J Wewer Albrechtsen; Jens J Holst
Journal:  Physiol Rep       Date:  2018-07

7.  The effects of high intensity interval training on appetite management in individuals with type 2 diabetes: influenced by participants weight.

Authors:  Saleh Afrasyabi; Syed Mohamad Marandi; Mehdi Kargarfard
Journal:  J Diabetes Metab Disord       Date:  2019-05-15

8.  Interleukin-6 in the central amygdala is bioactive and co-localised with glucagon-like peptide-1 receptor.

Authors:  Fredrik Anesten; Adrià Dalmau Gasull; Jennifer E Richard; Imre Farkas; Devesh Mishra; Lilly Taing; Fuping Zhang; Matti Poutanen; Vilborg Palsdottir; Zsolt Liposits; Karolina P Skibicka; John-Olov Jansson
Journal:  J Neuroendocrinol       Date:  2019-05-23       Impact factor: 3.627

Review 9.  Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1.

Authors:  Silvano Paternoster; Marco Falasca
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-11       Impact factor: 5.555

Review 10.  Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.

Authors:  Yulia A Nasykhova; Ziravard N Tonyan; Anastasiia A Mikhailova; Maria M Danilova; Andrey S Glotov
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.